Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2021 07:00 ET | Source: Opthea Limited

Opthea To Present at September Investor Conferences

MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
August 30, 2021 07:00 ET | Source: Opthea Limited

Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights

Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD) OPT-302 Granted FDA Fast Track Designation for Wet AMD Received FDA Waiver for Pediatric...
August 10, 2021 07:00 ET | Source: Opthea Limited

Opthea To Present at the H.C. Wainwright Ophthalmology Virtual Conference

MELBOURNE, Australia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
August 09, 2021 07:00 ET | Source: Opthea Limited

Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
July 06, 2021 07:00 ET | Source: Opthea Limited

Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

MELBOURNE, Australia, July 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
June 14, 2021 07:00 ET | Source: Opthea Limited

Opthea Appoints Company Secretary and Vice President of Finance

MELBOURNE, Australia, June 14, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
June 01, 2021 07:11 ET | Source: Opthea Limited

Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors

Board expands strengths in clinical and commercialization strategy OPT-302 pivotal Phase 3 trials for wet age-related macular degeneration (AMD) on track to reporting top-line data in 2023 ...
April 06, 2021 05:30 ET | Source: Opthea Limited

Opthea Company Secretary Resignation

MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of...
March 31, 2021 05:30 ET | Source: Opthea Limited

Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD

MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
March 15, 2021 05:30 ET | Source: Opthea Limited

Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD

MELBOURNE, Australia, March 15, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...